Le mode conseil est activé Arrêter

Sarepta Therapeutics, ordinary share
US8036071004, SRPT

Ajouter une action à la Liste de suivi
Sélectionnez tout Réinitialiser tout
Sarepta Therapeutics, pays — États-Unis
Aucunes données de trading
Représentation des données graphique | tableau
Source d'information - PJSC "MOEX". Toute autre diffusion des informations MOEX est interdite sans l'accord préalable de PJSC "MOEX".
Source d'information - PJSC "MOEX". Toute autre diffusion des informations MOEX est interdite sans l'accord préalable de PJSC "MOEX".
de
à
ADD-IN
Add-in Cbonds API
bond data api
Il faut s'enregistrer
Envoyer la demande d'accès accès
Plus de 2 500 éléments ont été trouvés, veuillez préciser votre demande
Pas de données sur la période choisie

Dernières cotations

explorer la base de données la plus complète

800 000

obligations globalement

Plus de 400

sources de prix

80 000

actions

9 000

ETF

suivre votre portefeuille de la manière la plus efficace
screener d'obligations
liste de surveillance
Excel ADD-IN
Obtenir l'accès

Émetteur

Profil
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular ...
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Montrer tout Cacher
  • Emetteur
  • Nom complet de l'emprunteur / émetteur
    Sarepta Therapeutics, Inc.
  • Secteur (industrie)
    Production de médicaments et biotechnologies

Rapports IFRS / US GAAP

2024
I q ang
2023
I q ang
II q ang
III q ang
IV q ang
2022
I q ang
II q ang
III q ang
IV q ang
2021
I q ang
II q ang
III q ang
IV q ang
2020
I q ang
II q ang
III q ang
IV q ang
2019
I q ang
II q ang
III q ang
IV q ang
2018
I q ang
II q ang
III q ang
IV q ang
2017
I q ang
II q ang
III q ang
IV q ang
2016
I q ang
II q ang
III q ang
IV q ang
2015
I q ang
II q ang
III q ang
IV q ang
2014
IV q ang
Afficher tout Masquer
Il faut s'enregistrer
Envoyer la demande d'accès accès

Indices contenant l’action

Indicateurs

Actualités

08/01/2024 Sarepta Therapeutics: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
22/06/2023 Sarepta Therapeutics: Regulation Fd Disclosure, Financial Statements And Exhibits
22/06/2023 Sarepta Therapeutics: Regulation Fd Disclosure, Financial Statements And Exhibits
08/06/2023 Sarepta Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibits
02/03/2023 Sarepta Therapeutics: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Financial Statements And Exhibits
Toutes les actualités de l'organisation

Autres actions et certificats de dépôt

Obligations nationales et internationales de l'émetteur

Détenteurs

Leaders de l'industrie

Vous devez vous inscrire pour y accéder.